- Home
- BTE vs IDYA Comparison
BTE vs IDYA Comparison
Compare BTE & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTE | IDYA |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BTE | IDYA |
|---|---|---|
| Price | $4.01 | $34.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $51.21 |
| AVG Volume (30 Days) | ★ 17.5M | 795.5K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.09 | $213.03 |
| P/E Ratio | $18.43 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $1.36 | $13.45 |
| 52 Week High | $4.13 | $39.28 |
Technical Indicators
Market Signals| Indicator | BTE | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 57.20 |
| Support Level | $3.59 | $32.85 |
| Resistance Level | N/A | $36.38 |
| Average True Range (ATR) | 0.17 | 1.41 |
| MACD | 0.01 | 0.39 |
| Stochastic Oscillator | 77.57 | 79.47 |
Price Performance
Historical ComparisonAbout BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.